Natural history and staging of chronic myelogenous leukaemia

J. Cortes, H. M. Kantarjian, S. Giralt, M. Talpaz

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


The natural history of chronic myelogenous leukaemia has changed in recent years, partly as a result of earlier diagnosis but mostly as a consequence of the availability of effective therapies that have the potential to eradicate the Philadelphia-positive clone. The prognostic models designed in the pre-interferon-α (IFN-α) era based on clinical characteristics of the disease are still useful in identifying different risk groups after treatment with IFN-α, but achieving a cytogenetic response with IFN-α is now the most important prognostic factor for survival. The significance of other molecular and biological variables remains to be determined.

Original languageEnglish (US)
Pages (from-to)277-290
Number of pages14
JournalBailliere's Clinical Haematology
Issue number2
StatePublished - 1997
Externally publishedYes


  • Chronic myoloid leukaemia
  • Cytogenetic response
  • Interferon
  • Prognosis
  • Stage

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Natural history and staging of chronic myelogenous leukaemia'. Together they form a unique fingerprint.

Cite this